Nearly 100 ASTRO members also called on legislators to protect patient access to high quality cancer care
WASHINGTON, D.C., May 25, 2016 – Radiation oncologists from across the United States convened on Capitol Hill yesterday to encourage members of Congress to invest in cancer research with sustainable and predictable funding and to protect patients’ access to high quality cancer care through value-based physician payment models. The 95 doctors were in Washington for approximately 150 meetings with Congressional leaders from their home districts and states as part of the American Society for Radiation Oncology’s (ASTRO) 13th annual Advocacy Day. read more
The Nederlandse Obesitas Kliniek and Medtronic Join Forces in the Battle Against Morbid Obesity
The Nederlandse Obesitas Kliniek (‘Dutch Obesity Clinic’, NOK) and Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, today announced that Medtronic has signed an agreement to enter into a strategic alliance, via a majority ownership position in NOK, with the goal of enhancing NOK’s ability to offer integrated, value-based healthcare solutions for the treatment of morbid obesity to more patients, in more locations around the world. read more
Chugai’s Bispecific Antibody “ACE910/Emicizumab” Phase l Data in Patients with Hemophilia A Published in The New England Journal of Medicine Online
TOKYO–(EON: Enhanced Online News)–Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the data from hemophilia A patients who participated in a Phase I study of the bispecific antibody emicizumab (ACE001JP study) was published online in The New England Journal of Medicine (NEJM) on May 25, 2016 (EST). Emicizumab is currently under development for hemophilia A. In this first-in-patient Phase I study, a once-weekly subcutaneous injection of emicizumab demonstrated a clinically acceptable safety profile and a potential benefit for preventing bleeding in hemophilia A patients, both with and without factor VIII (FVIII) inhibitors. read more
Vizient, Inc. Teams up with NQF and CDC to Issue Critical Guidance to Help Hospitals Better Manage Use of Antibiotics
IRVING, Texas–(EON: Enhanced Online News)–Decades of overprescribing and misuse of antibiotics have resulted in bacteria that are increasingly resistant to current drugs, creating a growing threat of new “superbugs” that are difficult, and sometimes even impossible, to treat. To help acute-care hospitals in the U.S. implement strategies to promote appropriate, safe use of antibiotics, the National Quality Forum (NQF), Centers for Disease Control and Prevention (CDC), and Hospital Corporation of America (HCA), led a team of more than 25 experts, which included representatives from Vizient, Inc., to create the Antibiotic Stewardship in Acute Care: A Practical Playbook. The Playbook is based on CDC’s Core Elements of Hospital Antibiotic Stewardship Programs. read more
World Experts Assemble to Debate Novel Psychoactive Substances
Over the last 10 years, many novel (or new) psychoactive drugs (NPS) have become available and around two new psychoactive substances are detected each week on the drug market in Europe. The regular development of new NPS, combined with the internet’s ability to spread information quickly, presents a number of challenges for public health across the globe. In order to increase knowledge and understanding about the nature and effects of NPS, as well as promote innovative solutions in the field, the fourth international conference on NPS takes place next week (30-31 May) in Budapest, Hungary.
SIPPET, an international randomized study, reports 87% higher incidence of inhibitors with recombinant factor VIII in patients with severe hemophilia A
PRNewswire/ — SIPPET, a study which involved 42 centers in 14 countries in Europe, North and South America, Africa and Asia was designed to definitively settle the long-debated question whether factor VIII concentrates from different sources (plasma-derived containing VWF or recombinant technology) differ in risk of inhibitor development in previously untreated children (PUPs) with severe hemophilia A.
What makes SIPPET unique is that it is the first randomized study in which patients were randomly assigned to receive either plasma-derived FVIII/VWF or recombinant factor VIII concentrates. Randomized studies are considered by physicians to provide the highest level of evidence, since randomization minimizes confounding factors that could bias the outcome. read more